New study checks safety of RSV prevention drug in vulnerable infants
NCT ID NCT06851806
First seen Jun 25, 2026 · Last updated Jul 10, 2026 · Updated 3 times
Summary
This study tests the safety of palivizumab, a drug given as monthly injections, in infants under 24 months who are at high risk for severe RSV disease. About 138 children born prematurely or with certain lung or heart conditions will receive up to 5 doses. Researchers will monitor for side effects and serious adverse events.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- palivizumab
- What this could lead to
- If successful, this study could confirm that palivizumab is safe for preventing severe RSV in high-risk infants, supporting its continued use.
- What could go wrong
- This is a small, open-label safety study with no placebo group, so it cannot prove effectiveness. Side effects may still occur.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS (RSV) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site
RECRUITINGHyderabad, 500084, India
-
Research Site
RECRUITINGKanpur, 208011, India
-
Research Site
RECRUITINGKolkata, 700073, India
-
Research Site
RECRUITINGMysore, 570001, India
-
Research Site
RECRUITINGPune, 411006, India
-
Research Site
RECRUITINGVidyanagar, Hubballi, 580022, India
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- One shot, two viruses? new mRNA vaccine targets RSV and hMPV
- New mRNA vaccine aims to shield against RSV
- Massive RSV vaccine study uses real-world data to see if shots prevent severe illness
- New RSV vaccine aims to shield adults from severe respiratory infection
- Scientists test RSV vaccine to boost immune memory
- New study tracks RSV in pregnant women and their babies